Tags

Type your tag names separated by a space and hit enter

Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005.
Br J Haematol. 2011 Sep; 154(5):600-11.BJ

Abstract

Philadelphia-chromosome acute lymphoblastic leukaemia (Ph+ ALL) is a subgroup of ALL with very high risk of treatment failure. We report here the results of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP/SHOP) in paediatric Ph+ ALL treated with intermediate-dose imatinib concurrent with intensive chemotherapy. The toxicities and outcome of these patients were compared with historical controls not receiving imatinib. Patients with Ph+ ALL aged 1-18years were enrolled in three consecutive ALL/SHOP trials (SHOP-94/SHOP-99/SHOP-2005). In the SHOP-2005 trial, imatinib (260mg/m(2) per day) was given on day-15 of induction. Allogeneic haematopoietic stem-cell transplantation (HSCT) from a matched related or unrelated donor was scheduled in first complete remission (CR1). Forty-three patients were evaluable (22 boys, median age 6·8years, range, 1·2-15). Sixteen received imatinib whereas 27 received similar chemotherapy without imatinib. Seventeen of 27 and 15 of 16 patients in the non-imatinib and imatinib cohort, respectively, underwent HSCT in CR1. With a median follow-up of 109 and 39months for the non-imatinib and imatinib cohorts, the 3-year event-free survival (EFS) was 29·6% and 78·7%, respectively (P=0·01). These results show that, compared to historical controls, intermediate dose of imatinib given concomitantly with chemotherapy and followed by allogeneic HSCT markedly improved early EFS in paediatric Ph+ ALL.

Authors+Show Affiliations

Paediatric Haematology Department, Hospital Sant Joan de Déu de Barcelona Universitat de Barcelona, Barcelona, Spain. srives@hsjdbcn.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21707583

Citation

Rives, Susana, et al. "Intermediate Dose of Imatinib in Combination With Chemotherapy Followed By Allogeneic Stem Cell Transplantation Improves Early Outcome in Paediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia (ALL): Results of the Spanish Cooperative Group SHOP Studies ALL-94, ALL-99 and ALL-2005." British Journal of Haematology, vol. 154, no. 5, 2011, pp. 600-11.
Rives S, Estella J, Gómez P, et al. Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. Br J Haematol. 2011;154(5):600-11.
Rives, S., Estella, J., Gómez, P., López-Duarte, M., de Miguel, P. G., Verdeguer, A., Moreno, M. J., Vivanco, J. L., Couselo, J. M., Fernández-Delgado, R., Maldonado, M., Tasso, M., López-Ibor, B., Lendínez, F., López-Almaraz, R., Uriz, J., Melo, M., Fernández-Teijeiro, A., Rodríguez, I., & Badell, I. (2011). Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. British Journal of Haematology, 154(5), 600-11. https://doi.org/10.1111/j.1365-2141.2011.08783.x
Rives S, et al. Intermediate Dose of Imatinib in Combination With Chemotherapy Followed By Allogeneic Stem Cell Transplantation Improves Early Outcome in Paediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukaemia (ALL): Results of the Spanish Cooperative Group SHOP Studies ALL-94, ALL-99 and ALL-2005. Br J Haematol. 2011;154(5):600-11. PubMed PMID: 21707583.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL-94, ALL-99 and ALL-2005. AU - Rives,Susana, AU - Estella,Jesús, AU - Gómez,Pedro, AU - López-Duarte,Mónica, AU - de Miguel,Purificación García, AU - Verdeguer,Amparo, AU - Moreno,Maria José, AU - Vivanco,José Luis, AU - Couselo,José Miguel, AU - Fernández-Delgado,Rafael, AU - Maldonado,Marisol, AU - Tasso,María, AU - López-Ibor,Blanca, AU - Lendínez,Francisco, AU - López-Almaraz,Ricardo, AU - Uriz,Javier, AU - Melo,Montserrat, AU - Fernández-Teijeiro,Ana, AU - Rodríguez,Isidoro, AU - Badell,Isabel, Y1 - 2011/06/28/ PY - 2011/6/29/entrez PY - 2011/6/29/pubmed PY - 2011/10/28/medline SP - 600 EP - 11 JF - British journal of haematology JO - Br J Haematol VL - 154 IS - 5 N2 - Philadelphia-chromosome acute lymphoblastic leukaemia (Ph+ ALL) is a subgroup of ALL with very high risk of treatment failure. We report here the results of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP/SHOP) in paediatric Ph+ ALL treated with intermediate-dose imatinib concurrent with intensive chemotherapy. The toxicities and outcome of these patients were compared with historical controls not receiving imatinib. Patients with Ph+ ALL aged 1-18years were enrolled in three consecutive ALL/SHOP trials (SHOP-94/SHOP-99/SHOP-2005). In the SHOP-2005 trial, imatinib (260mg/m(2) per day) was given on day-15 of induction. Allogeneic haematopoietic stem-cell transplantation (HSCT) from a matched related or unrelated donor was scheduled in first complete remission (CR1). Forty-three patients were evaluable (22 boys, median age 6·8years, range, 1·2-15). Sixteen received imatinib whereas 27 received similar chemotherapy without imatinib. Seventeen of 27 and 15 of 16 patients in the non-imatinib and imatinib cohort, respectively, underwent HSCT in CR1. With a median follow-up of 109 and 39months for the non-imatinib and imatinib cohorts, the 3-year event-free survival (EFS) was 29·6% and 78·7%, respectively (P=0·01). These results show that, compared to historical controls, intermediate dose of imatinib given concomitantly with chemotherapy and followed by allogeneic HSCT markedly improved early EFS in paediatric Ph+ ALL. SN - 1365-2141 UR - https://www.unboundmedicine.com/medline/citation/21707583/Intermediate_dose_of_imatinib_in_combination_with_chemotherapy_followed_by_allogeneic_stem_cell_transplantation_improves_early_outcome_in_paediatric_Philadelphia_chromosome_positive_acute_lymphoblastic_leukaemia__ALL_:_results_of_the_Spanish_Cooperative_Group_SHOP_studies_ALL_94_ALL_99_and_ALL_2005_ L2 - https://doi.org/10.1111/j.1365-2141.2011.08783.x DB - PRIME DP - Unbound Medicine ER -